Carroll Financial Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $42K | Sell |
189
-74
| -28% | -$14.4K | ﹤0.01% | 772 |
|
|
2021
Q3 | $47K | Sell |
263
-161
| -38% | -$31.4K | ﹤0.01% | 759 |
|
|
2021
Q2 | $85K | Buy |
424
+10
| +2% | +$2.09K | ﹤0.01% | 631 |
|
|
2021
Q1 | $88K | Buy |
414
+48
| +13% | +$10.5K | 0.01% | 602 |
|
|
2020
Q4 | $86K | Hold |
366
| – | – | 0.01% | 548 |
|
|
2020
Q3 | $99K | Sell |
366
-64
| -15% | -$17.7K | 0.01% | 484 |
|
|
2020
Q2 | $124K | Buy |
430
+147
| +52% | +$39.9K | 0.01% | 431 |
|
|
2020
Q1 | $67K | Buy |
283
+20
| +8% | +$4.59K | 0.01% | 515 |
|
|
2019
Q4 | $57K | Buy |
263
+50
| +23% | +$10.1K | ﹤0.01% | 621 |
|
|
2019
Q3 | $36K | Sell |
213
-5
| -2% | -$885 | ﹤0.01% | 687 |
|
|
2019
Q2 | $39K | Sell |
218
-48
| -18% | -$8.39K | ﹤0.01% | 663 |
|
|
2019
Q1 | $48K | Buy |
266
+59
| +29% | +$10.9K | ﹤0.01% | 580 |
|
|
2018
Q4 | $36K | Hold |
207
| – | – | ﹤0.01% | 546 |
|
|
2018
Q3 | $39K | Hold |
207
| – | – | ﹤0.01% | 557 |
|
|
2018
Q2 | $35K | Buy |
207
+161
| +350% | +$25K | ﹤0.01% | 558 |
|
|
2018
Q1 | $7K | Hold |
46
| – | – | ﹤0.01% | 943 |
|
|
2017
Q4 | $6K | Hold |
46
| – | – | ﹤0.01% | 970 |
|
|
2017
Q3 | $7K | Hold |
46
| – | – | ﹤0.01% | 912 |
|
|
2017
Q2 | $5K | Hold |
46
| – | – | ﹤0.01% | 994 |
|
|
2017
Q1 | $5K | Hold |
46
| – | – | ﹤0.01% | 996 |
|
|
2016
Q4 | $3K | Hold |
46
| – | – | ﹤0.01% | 1027 |
|
|
2016
Q3 | $4K | Hold |
46
| – | – | ﹤0.01% | 1002 |
|
|
2016
Q2 | $3K | Hold |
46
| – | – | ﹤0.01% | 1027 |
|
|
2016
Q1 | $3K | Hold |
46
| – | – | ﹤0.01% | 1008 |
|
|
2015
Q4 | $5K | Hold |
46
| – | – | ﹤0.01% | 877 |
|
|
2015
Q3 | $5K | Sell |
46
-23
| -33% | -$2.96K | ﹤0.01% | 857 |
|
|
2015
Q2 | $9K | Buy |
+69
| New | +$8.7K | ﹤0.01% | 737 |
|
|
2015
Q1 | – | Sell |
-60
| Closed | -$7.19K | – | 872 |
|
|
2014
Q4 | $7K | Sell |
60
-58
| -49% | -$6.53K | ﹤0.01% | 534 |
|
|
2014
Q3 | $13K | Hold |
118
| – | – | ﹤0.01% | 528 |
|
|
2014
Q2 | $11K | Buy |
118
+30
| +34% | +$2.1K | ﹤0.01% | 593 |
|
|
2014
Q1 | $6K | Buy |
88
+28
| +47% | +$2.22K | ﹤0.01% | 629 |
|
|
2013
Q4 | $4K | Hold |
60
| – | – | ﹤0.01% | 649 |
|
|
2013
Q3 | $4K | Hold |
60
| – | – | ﹤0.01% | 636 |
|
|
2013
Q2 | $4K | Buy |
+60
| New | +$4.42K | ﹤0.01% | 513 |
|
Other funds holding VRTX
Carroll Financial Associates's VRTX Position: Q4 2021 in Review
Carroll Financial Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 28% in Q4 2021, selling an estimated $14.4K and leaving 189 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #772.
Carroll Financial Associates first reported a position in VRTX in Q2 2013 and has held it in 34 quarters since. The position peaked at $124K in Q2 2020. 1,034 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.
- Carroll Financial Associates held 189 shares of Vertex Pharmaceuticals worth $42K as of Q4 2021.
- Carroll Financial Associates sold 74 Vertex Pharmaceuticals shares in Q4 2021, an estimated $14.4K.
- Vertex Pharmaceuticals made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #772 holding.
- Carroll Financial Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
- Carroll Financial Associates's Vertex Pharmaceuticals position peaked at $124K in Q2 2020.
- 1,034 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.